ESR1 and breast carcinoma: Similarly, we have reported that high tumor expression of cytoplasmic SK1 correlates with shorter disease-specific survival and recurrence time in estrogen receptor-positive (ER+) breast cancer patients (Long et al., 2010; Watson et al., 2010).